Showing 1711-1720 of 2526 results for "".
- NIH-Led Science Team Defines Elements of Cerebral Vision Impairmenthttps://modernod.com/news/nih-led-science-team-defines-elements-of-brain-based-leading-cause-of-childhood-vision-loss/2482557/Cerebral (or cortical) vision impairment (CVI) is a leading cause of childhood vision impairment in the United States and other industrialized nations, affecting at least 3% of primary school children. As vision is closely tied to learn
- Melt Pharmaceuticals Announces Positive Phase 3 Trial Results for MELT-300 Sedation Solutionhttps://modernod.com/news/melt-pharmaceuticals-announces-positive-phase-3-trial-results-for-melt-300-sedation-solution/2482552/Melt Pharmaceuticals announced positive topline results from its pivotal phase 3 trial of MELT-300. This novel, non-intravenous, non-opioid tablet is designed to provide effective sedation during cataract surgery. The phase 3 study, conducted under a Special Protocol Assessment (SPA) ag
- Myze Launches 'The Daily Lid Wipe' for Eyelid Hygienehttps://modernod.com/news/myze-launches-the-daily-lid-wipe-to-elevate-daily-eye-care-partnering-with-leading-eye-health-experts/2482543/In a move to prioritize eyelid hygiene and make it a core component of everyday self-care routine, myze has unveiled its first branded product, The Daily Lid Wipe. The Daily Lid Wipe, formulated with input from dry eye experts Laura M. Periman, MD, and Cecelia Koett
- Atsena and Nippon Shinyaku Enter Strategic Collaboration for ATSN-101 Advancementhttps://modernod.com/news/atsena-therapeutics-and-nippon-shinyaku-enter-strategic-collaboration-for-atsn-101-advancement/2482542/Atsena Therapeutics has entered into an exclusive licensing agreement with Nippon Shinyaku for the commercialization of investigational gene therapy ATSN-101 for Leber congenital amaurosis. Atsena's ATSN-101 is a subretinal AAV5 gene therapy undergoing evaluatio
- Kian Capital and RF Investment Partners to Launch US VisionMed Partnershttps://modernod.com/news/kian-capital-and-rf-investment-partners-to-launch-us-visionmed-partners/2482540/Kian Capital Partners and RF Investment Partners, two private investment firms, have announced the launch of US VisionMed Partners, a management services organization (MSO). US VisionMed Partners aims to elevate optometry practices by offering a unique model focused on medically advance
- Oklahoma Neonatologist-Researcher Earns NIH Grant to Advance Retinopathy of Prematurityhttps://modernod.com/news/oklahoma-neonatologist-researcher-earns-nih-grant-to-advance-retinopathy-of-prematurity/2482537/Faizah Bhatti, MD, was the first to discover the presence of surfactant protein A in the eye–a key protein related to blood vessel growth and previously believed to only exist in the lung. Now, the University of Oklahoma neonatologist and researcher has earned a 5-year, $2.3 million grant f
- Konan Medical USA Launches objectiveFIELD Visual Field Analyzerhttps://modernod.com/news/konan-medical-usa-launches-objectivefield-visual-field-analyzer/2482534/Konan Medical USA announced the commercial launch of its objectiveFIELD (OFA) visual field analyzer. The OFA is an objective visual field analyzer designed to detect visual field abnormalities using pupillary responses. According to Konan Medical, unlike traditional subjectiv
- Arctic Vision Executes Collaboration Agreement with Santen for ARVN001 for the Treatment of Uveitic Macular Edemahttps://modernod.com/news/clearside-biomedical-partner-arctic-vision-executes-commercial-collaboration-agreement-with-santen-pharmaceutical-co-for-arvn001-suprachoroidal-space-injection-therapy-for-the-treatment-of-uveitic-macular-edema/2482529/Clearside Biomedical announced that its Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical for ARVN001, branded in the United States as Xipere, for the treatment of uveitic macular edema
- FELIQS Receives FDA Fast Track Designation for FLQ-101, a First-in-Class Small Molecule to Prevent Retinopathy of Prematurityhttps://modernod.com/news/feliqs-receives-fda-fast-track-designation-for-flq-101-a-first-in-class-small-molecule-to-prevent-retinopathy-of-prematurity/2482526/FELIQS announced that the US Food and Drug Administration (FDA) has granted its lead asset, FLQ-101, Fast Track designation for the prevention of retinopathy of prematurity (ROP). The company plans to conduct a Phase1b/2 study of FLQ-101 (tROPhy-1 study) both in the United States and Ja
- LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMDhttps://modernod.com/news/lumithera-obtains-fda-authorization-of-valeda-treatment-for-dry-amd/2482525/The FDA has granted authorization to LumiThera allowing the company to market its Valeda Light Delivery System. This approval, made under the De Novo authorization pathway, makes Valeda the first FDA-authorized device to treat vision loss in patients with dry AMD.